Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Site Partners, LLC

Neither a doctor nor a teaching hospital

Research payments

$264,311

61 payments

Through program year 2025, Clinical Site Partners, LLC is reported as receiving $264,311 in research payments, across 61 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $71,586 21
2024 Research $66,025 14
2023 Research $26,825 10
2022 Research $99,874 16

Breakdown

Who paid Research payments · program years 2022–2025
  1. Mylan Specialty L.P. $130,873 25 payments
  2. CSL Behring $108,982 31 payments
  3. Genentech, Inc. $24,455 5 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis $108,982 31 payments
  2. A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $75,419 11 payments
  3. A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $28,629 4 payments
  4. A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) $26,825 10 payments
  5. P2 Study of Mtps9597a in Subjects With Csu $24,455 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record